Document 4a2DVXRM3xe0KkeXQOKQ52Loa

fiz Sa % 3 emer FY 020). 1378 AR 226 _ 025 UNI TED STA TESWEANSVHIIRNOGNTOMNE,NTDA.CL. P2R0O4T6E0CTION AG E N C Y FRULU2Y February 14, 2001 Rin Gand Kemet DuPont Haskell Laboratory Director, Applied Toxicology Cont Bony I Elkton Road, P.O. Box 50 Newark, DE 19714-0050 PreTvoeeonrSnmFcseesronrcoeessmo Hp cpt Dear Mr. Kennedy: FY1-00-001378 Regarding your January 25, 2001, FYI submission on ammonium perfluorooctanoate, please explain your rationale for reporting the results in this submission, as well as in your earlier s8(ub).misIsnipoanrotifcuJluarn,e t2h3e,r2e0s0ul0t,s aosf`tvhoeluhnutamraynFbYlIoosdubsmeirsusmiotnessrtastfhoerrtahmamnonuinduemrpTeSrfClAuoSreocotcitaonne, in combination with possible human health hazard been considered for reporting under the Section concerns, indicate that these 8(e) requirementsof TSCA. results should have Enclosed is the first pageofyour submission and a copy of "Support Information for Confidentiality Claims". Please cite the assigned FYI number and address your response to: Document Control Office (7407) Room G99 East Tower ATTN: FYI Officeof Pollution Prevention and Toxics U.S. Environmental Protection Agency < 4`W0a1shMingSttroene,t,DS.C..W.20460-0001 o= Sinegrely, 7 7 2; Richard H. Hefter, Chief High Production Volume Chemicals Branch Enclosures BUCHER 85010000005 RaritItomiet AdeiossURL)c hi n apngoa v ek 5 Ferm